Innovative Cellular Therapeutics Holdings, Ltd.

Innovative Cellular Therapeutics, Inc.

Shanghai Jiaotong University

Innovative Cellular Therapeutics Co., Ltd.

Li Mao

Lei Xiao

Chengfei Pu

Zhiyuan Cao

Zhao Wu

He Sun

Wensheng Wang

Xu Wang

Ping Zhang

Zhiyuan Zhang

Ming Yan

Qin Xu

Mao Bi

Jianjun Zhang

Chenping Zhang

Wantao Chen

Jinsong Pan

Yan Lv

Rongxin Deng

Weiliu Qiu

The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. The compositions include CAR comprising an extracellular domain that binds a siglec protein or a receptor that binds the peptide hormone kisspeptin.

Chimeric antigen receptor cells for treating solid tumor

The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using modified T cells in which TRAC genes are inactivated using a Zinc-finger nuclease (ZFN). The ZFN may include a first zinc finger protein (ZFP) that binds a first target site in a T-cell receptor alpha constant (TRAC) gene and a second ZFP that binds a second target site in the TRAC gene.

Chimeric antigen receptor (CAR) and T cell receptor (TCR) modified T cells

Gambogenic acid derivatives having a structure shown as Formula (I) or (II), salts, preparation method and application thereof in the treatment of tumor. Compared with gambogenic acid, the gambogenic acid derivatives exhibit more potent anti-tumor activities.

Gambogenic acid derivatives, preparation method and application thereof

Growing community of inventors

Shanghai, China

Li Mao